Bormann-Kennedy Barbara-Jean Anne

Director at XERS

Sold, on record
$204k
Dollars the filings state
Form 4 sales
2
Latest Jun 4, 2026
Form 144 notices
1
Proposed sales
Companies
1
Filed as an executive or holder

Companies

  • XERSXeris Biopharma Holdings, Inc.Director

Sales by reason

2
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Timeline

  1. 1 Form 144 notice XERSNotice
    Dec 12, 2025 2025

    Filed to sell 15,000 shares ($105k)

    Bormann-Kennedy Barbara-Jean Anne, Director

    10b5-1 planFirst sale on recordFiling

  2. 2 Form 4 sale XERSRoutine
    Dec 12, 2025 same day

    Sold 15,000 shares at $7.09 ($106k)

    Bormann-Kennedy Barbara-Jean Anne, Director

    10b5-1 planSold 9.5% of holdings ($1.1M position)142,500 shares leftFirst sale on recordFollows a Form 144Filing

  3. 3 Form 4 sale XERSRoutine
    Jun 4, 2026 +174 days

    Sold 16,000 shares at $6.09 ($97k)

    Bormann-Kennedy Barbara-Jean Anne, Director

    10b5-1 planSold 11.2% of holdings ($868k position)126,500 shares leftFiling

Every transaction

Loading transactions…

Sales and notices (3)

Form 144 notices and Form 4 sales by Bormann-Kennedy Barbara-Jean Anne
Source
Jun 4, 2026Jun 5, 2026XERSDirectorForm 4 sale16,000$97k11.2%RoutineSEC
Dec 12, 2025Dec 15, 2025XERSDirectorForm 4 sale15,000$106k9.5%RoutineSEC
Dec 12, 2025Dec 12, 2025XERSDirectorForm 144 notice15,000$105kNoticeSEC